Both GHRP-2 and GHRP-6 tend to cause fluctuations in the body's natural production of prolactin and cortisol, which can also be concerning from a hormonal standpoint
[1] In phase 3 trials, orforglipron produced 12.4% weight loss (27.3 lbs) at 72 weeks less than injectable tirzepatide (20%) but comparable to oral semaglutide
Multi-level growth factor signaling accelerates tissue repair, reduces inflammation, and shortens recovery time after training or injury
BPC-157 is not approved for therapeutic use in Australia, and most evidence comes from animal studies rather than knee patient trials
GLP-1 weight loss for non-diabetics How do GLP-1 weight loss medications work
Lawyers handling GLP-1 litigation often work with physicians, economic experts, and other specialists to assess the full financial and personal impact of an injury, including future medical needs and long-term disability